Randomised controlled trial of plasma cell depletion for severe Graves’ disease.

• Study stage: Recruiting
• Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder: MRC
• Therapeutic area: Metabolic and Endocrine
• Type of study: CTIMP

Aim: To determine if daratumumab modulates the humoral immune response in Graves’ disease patients

Primary Outcome:

Change in serum TRAb antibodies from baseline to 12 weeks compared to change in placebo group

• Population: Adult
• Phase: IIa
• Design: Adaptive
• Setting: Secondary care
• Planned Sample Size: 30